Dr. Miranda is proud to offer the latest injectable treatment in wrinkle-fighting technology, LAVIV™ (azficel-T).
LAVIV™ (azficel-T) is the first and only FDA-approved therapy that uses your own collagen-producing cells (fibroblasts) to improve the look of your smile lines—for results that are totally unique to you.
Fibroblasts are skin cells that produce collagen and play a key role in the continued health of your skin.
Collagen provides firmness and structure to the skin and is essential in supporting the dermis (or middle layer) of the skin. The dermis is a supportive and elastic connective tissue. It is here where fibroblasts are found.
As we age, our fibroblasts reduce in number and the collagen matrix that makes up most of the dermis breaks down. This creates an imbalance that causes the dermis to become less stretchable, less resilient, more lax, and prone to wrinkling.
(Composition of the skin)
1. Skin Sample Taken
Dr. Miranda will take small skin samples from behind your ear with the use of a local anesthetic.
2. Creating Your LAVIV™
Your skin samples are sent to the FDA-inspected Fibrocell Science manufacturing facility, where they are expanded into millions of new fibroblast cells to make your LAVIV™.
All of your cells are cryopreserved (frozen) and those that are not immediately used are stored at Fibrocell Science’s FDA-inspected manufacturing facility for future use.
Your LAVIV™ fibroblast cell therapy is ready in about 3 months. It will be shipped directly to Dr. Miranda’s office and will arrive on the same day as your first LAVIV™ treatment session.
3. LAVIV™ Personalized Treatment Sessions
Using a small needle, Dr. Miranda will inject LAVIV™ directly into your smile lines. You will receive 3 injections of LAVIV™, spaced at intervals of 3 to 6 weeks. When patients were assessed 6 months after the third and final treatment, LAVIV had effectively improved the appearance of smile line wrinkles.
In more recent news, a British company known as Pharmacells, has licensed the technology to harvest a new type of somatic cell – called a blastomere-like somatic cell (CORR) – which is found circulating in the blood. Researchers hope to spur the growth of new fibroblast skin cells with only a patient’s blood sample; clinical trials are set to begin within the next 12 months. They believe the procedure could be commercially available in just three years, potentially revolutionizing the market for anti-aging treatments.